AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05368090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-RFA of left adrenal tumour in MACS with bilateral overproduction, debulking group
Description: Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
Study NCT05967143 — intervention group
Intervention type: DEVICE
Intervention: SIRT
Description: Selective internal radiation therapy with SIR-Spheres Y90 resin microspheres.
Study NCT04915248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent.
Study NCT04915248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent.
Study NCT04915248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent.
Study NCT04775082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.~The dose will increase each week over 4 or 5 weeks until the final dose is reached.
Study NCT04775082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
Study NCT04596553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Essential Amino Acid
Description: Immediately following the exercise intervention participants will consume their assigned essential amino acid supplement
Study NCT04596553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Peptide
Description: Immediately following the exercise intervention participants will consume their assigned collagen peptide supplement
Study NCT04596553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin Placebo
Description: Immediately following the exercise intervention participants will consume their assigned maltodextrin supplement
Study NCT05269251 — intervention group
Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy (NIRS)
Description: After the brachial plexus block, the regional oxygen saturation (rSO2) was monitored for 30 minutes with the Regional Oximetry System (O3™, Masimo, Irvine, CA) and the radial artery diameter with ultrasound in the same period.
Study NCT05720000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Patient will receive the application of the low-power 660 nm Newskin MMO red LED in the immediate postoperative period. The application will be made punctually over the entire length of the wire, which measures 5 cm, totaling 10 application points with 1 cm of distance between them. The LED application will be repeated twice a week, with a minimum interval of 48 hours, totaling 9 laser applications over 30 days.
Study NCT05720000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDO thread
Description: The participant's face will be cleaned with a 0.2% chlorhexidine solution. 0.1 ml of injectable anesthetic (2% lidocaine hydrochloride without vasoconstrictor, XYlestesin) will be administered in the skin layer at the point of incision in the glabellar region with a 30-gauge needle. A subincision will be made with a 21-gauge cannula in the glabellar ridge and then an injectable thread will be applied in the deep dermal layer below the glabellar ridge in the same direction as it.
Study NCT05720000 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PDO thread
Description: The participant's face will be cleaned with a 0.2% chlorhexidine solution. 0.1 ml of injectable anesthetic (2% lidocaine hydrochloride without vasoconstrictor, XYlestesin) will be administered in the skin layer at the point of incision in the glabellar region with a 30-gauge needle. A subincision will be made with a 21-gauge cannula in the glabellar ridge and then an injectable thread will be applied in the deep dermal layer below the glabellar ridge in the same direction as it.
Study NCT04901728 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cultural Domain Analysis
Description: 80 and up to a maximum of 120 participants
Study NCT05115942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone capsules
Description: After randomization, the experimental group were orally received hydronidone capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d,30 min before meals for 52 weeks.
Study NCT05115942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo capsules
Description: After randomization, The control group were orally received placebo capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d, 30 min before meals for 52 weeks.
Study NCT04901728 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group Discussion
Description: At least 18 and up to a maximum of 60 participants
Study NCT04901728 — intervention group
Intervention type: BEHAVIORAL
Intervention: In-depth interview
Description: At least 18 and up to a maximum of 36 participants
Study NCT04839926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg CY150112
Description: single oral CY150112 while fasting on day 1.
Study NCT05339308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium oil (BetterYou) dermal application
Description: 10 sprays (200 mg) of magnesium oil (BetterYou) will be applied to skin covering knee extensor muscles. The magnesium oil will be applied only once
Study NCT04839926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18mg CY150112
Description: single oral CY150112 while fasting on day 1.
Study NCT04839926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24mg CY150112
Description: single oral CY150112 while fasting on day 1.
Study NCT05339308 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Natural mineral-free oil (10 sprays) will be applied as the control condition. This will be done only once
Study NCT06473987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized cognitive-sensorimotor VR/AR training
Description: Thinking task integrated walking and balance training program
Study NCT06473987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional dual-task training
Description: Walking and balance training similar to standard of care group but will also perform additional thinking tasks during training
Study NCT06473987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard walking and balance training
Study NCT05864768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegan/vegetarian diet
Description: At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths >3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values >20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded.
Study NCT05776810 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Test: Head Up Tilt Table (HUT)
Description: Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT \[protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes\]
Study NCT05776810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Implantable Loop Recorder
Description: ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
Study NCT05629936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Digital interdisciplinary intervention
Description: Digital medication interview, comprehensive medication review, interdisciplinary patient-centred discussions, follow-ups
Study NCT05864768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omnivorous diet
Description: At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths >3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values >20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded.
Study NCT05988749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofourmis Digital Platform
Description: The intervention is a combination of the American Heart Association's Digital Heart Failure CarePlans and Education Content, delivered through and combined with the Biofourmis Platform. Patients enrolled in this arm will wear the device for 90 days and provide data to the participant's care team.
Study NCT06493851 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: The HBOT protocol consists of 6 weeks protocol including 5 daily HBOT sessions per week (total of 30), each session lasts 90 minutes, of 100% oxygen at 2 atmosphere absolute (ATA) with 5-minute air breaks every 20 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux Starmed 2700, Germany) located at the Sagol center for hyperbaric medicine and research, Shamir (Assaf-Harofeh) Medical Center, Israel.
Study NCT06493851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: The HBOT protocol consists of 6 weeks protocol including 5 daily HBOT sessions per week (total of 30), each session lasts 90 minutes, of 100% oxygen at 2 atmosphere absolute (ATA) with 5-minute air breaks every 20 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux Starmed 2700, Germany) located at the Sagol center for hyperbaric medicine and research, Shamir (Assaf-Harofeh) Medical Center, Israel.
Study NCT06565988 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Decoria Voluma
Description: Decoria® Voluma medical device is a sterile, single use Hyaloronic acid based dermal filler intended for aesthetic use, provided in the form of a nonpyrogenic, viscoelastic gel. It is composed of highly purified sodium hyaluronate of high molecular weight, dissolved in a physiological buffer at pH 6.0-7.5. The sodium hyaluronate is derived from microbial fermentation and is stabilized by crosslinking with the chemical agent BDDE (1,4 Butanediol Diglycidyl Ether).~Decoria® Voluma dermal fillers are injected into dermal tissue for the correction of midface volume deficit by tissue augmentation in cheek region, supporting overlying tissue to shape facial contours to desired level of correction. This is possible due to the capacity of HA to attract and bind large amounts of water, forming a viscous gel.~Appropriate injection volume for the cheek region(s) will be determined by the Treating investigator according to IFU.
Study NCT06533397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus floor elevation (SFE)
Description: Patients rinse with 0.2% chlorhexidine solution for one minute before surgery. Under local anesthesia, a mucoperiosteal flap is raised from a midcrestal incision and two relieving incisions. Lateral window osteotomies are carried out using diamond burs. The Schneiderian membrane is carefully elevated and the synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) (2-3 cm3) is packed in the defect with light force. The buccal flap is then mobilized to allow tension-free primary closure. The margins are stabilized with single interrupted sutures. Antibiotics (1 g amoxicillin-clavulanate twice a day for 5 days, or in case of side effects or known allergy to penicillin, 300 mg clindamycin 4 times a day for 4 days), anti-inflammatory drugs (50 mg diclofenac 3 times a day for 3 days), and chlorhexidine mouthwash (twice a day for 21 days from the first day after surgery) are prescribed. Suture removal takes place after 10 days.
Study NCT06152198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Allocation to hip arthroplasty or internal fixation. The choice between hemi- or total hip arthroplasty in the arthroplasty group and type of osteosynthesis are the surgeon preference.
Study NCT06533397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: preoperative cone beam computed tomography (CBCT)
Description: A CBCT scan is performed before SFE surgery to evaluate the anatomy and pathologies of the maxillary sinus.
Study NCT06152198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Allocation to hip arthroplasty or internal fixation. The choice between hemi- or total hip arthroplasty in the arthroplasty group and type of osteosynthesis are the surgeon preference.
Study NCT06421974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DaVinci si or xi system
Description: In this study, subjects were randomly divided into an experimental group (robot-assisted radical resection of right colon cancer group, referred to as robotic surgery group) and a control group (laparoscopic radical resection of right colon cancer group, referred to as laparoscopic surgery group).
Study NCT06421974 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic radical resection
Description: In this study, subjects were randomly divided into an experimental group (robot-assisted radical resection of right colon cancer group, referred to as robotic surgery group) and a control group (laparoscopic radical resection of right colon cancer group, referred to as laparoscopic surgery group).
Study NCT06094920 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin 10 MG
Description: Oral administration
Study NCT06094920 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Finerenone
Description: Oral administration.~Finerenone treatment may be initiated if serum potassium levels are ≤5.0 mmol/L. Conversely, if serum potassium levels are >5.0 mmol/L, the initiation of finerenone treatment should be avoided. In such cases, a second serum potassium measurement will be performed two days later. If serum potassium levels are ≤5.0 mmol/L, these patients can still be considered for inclusion. However, if serum potassium levels are >5.0 mmol/L again, these patients will be excluded, and an assessment of the underlying cause(s) of hyperkalaemia will be conducted.~The recommended initial dose of finerenone is determined based on eGFR, which will be assessed prior to the commencement of the trial. If eGFR is ≥60 mL/min/1.73m2, the dose will be set at 20 mg once daily. If eGFR is ≥25 to \<60, the dose will be set at 10 mg once daily. Participants with an eGFR \<25 are not advised to undergo finerenone treatment and will be excluded from the study.
Study NCT06094920 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Withings BPM Connect
Description: CE marked and clinically validated blood pressure monitor. Clinical trial results are within the margin of acceptance defined by the internationally recognized evaluation standard of blood pressure monitors ANSI/AAMI/ISO 81060-2:2013, EN ISO 81060-2:2014, developed by the European Society of Hypertension, British Hypertension Society and Association for the Advancement of Medical Instrumentation/American Heart Association.~Blood pressure will be measured by the participants once daily on 40 days. Three consecutive measurements are taken.
Study NCT06094920 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Withings Body
Description: CE marked and clinically validated advanced Wi-Fi smart scale.~Body weight will be measured by the participants once daily on 49 days.
Study NCT06094920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PeeSpot Urine Collection Device
Description: Biochemical urine data will be collected using first-morning void urine samples. Participants will obtain urine samples with the PeeSpot device, a validated tool designed for the collection and preservation of small urine volumes. This device comprises a urine absorption pad, a holder, a tube, and a lid. Patients can void directly onto the absorption pad while it is placed in the holder. Following voiding, the pad and holder are inserted into the tube, sealed with the lid, and stored in a refrigerator until they are sent to the laboratory using a biological materials envelope (PolyMed, DaklaPack, Europe). Through the incorporation of an inert hygroscopic polymer, the pad efficiently absorbs 1.2 mL of urine, and with the addition of various preservatives, the urine remains stable for up to four days. The investigators will employ the PeeSpot to determine the first-morning void levels of albumin, creatinine, sodium, potassium, glucose, urea, and osmolality once daily on 28 days.
Study NCT06094920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hem-Col Capillary Blood Collection Device
Description: Capillary blood samples will be obtained using a BD Microtainer® Contact-Activated Lancet (Franklin Lakes, New Jersey, USA) once daily on 17 days. These blood samples will be collected into Hem-Col® tubes (Hem-Col, Labonovum, Limmen, the Netherlands), specifically designed for collection of capillary blood acquired through a finger prick. The Hem-Col microtube is equipped with an anticoagulant and a preservation buffer, enhancing the stability of analytes in whole blood. These Hem-Col tubes have the dimensions of standard blood collection tubes and are constructed from polyethylene, featuring a pierceable cap made of thermoplastic elastomers. Each tube incorporates a liquid barrier, with the inner part preventing the loss of Hem-Col preservation fluid and the outer part serving as a scoop for collecting blood from a finger prick. The Hem-Col lithium heparin tubes will be utilized for the analysis of creatinine, potassium, hsCRP, haematocrit, cystatin C, and fasting plasma glucose.
Study NCT06533397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: postoperative CBCT
Description: A CBCT scan is performed following the 3- or 6-month-long healing period after SFE to evaluate the anatomy and healing of the augmented bone and the maxillary sinus.
Study NCT06533397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bone core biopsy
Description: At the time of dental implant placement, the first step of the implant bed preparation is performed using a trephine drill to harvest a bone core biopsy sample from the augmented bone. The biopsy sample is harvested from the implant bed, this way the patient is spared of excess surgical burden as this bone would be removed even if no biopsy sample was harvested during dental implant placement. The bone core biopsy samples are subjected to histomorphometric and microCT analysis.
Study NCT06533397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Description: Following the 3- or 6-month-long healing period following SFE, dental implants are placed non-submerged in the augmented bone under local anesthesia.
Study NCT06533397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixed dental prosthesis (FDP) fabrication
Description: 3 months after dental implant placement, fixed dental prostheses are delivered on the dental implants.
Study NCT06533397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bone grafting
Description: A synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) is used during SFE.